HLS Therapeutics Reports Annual Meeting Results
A total of 21,098,254 Common Shares, or 66.32% of the total Common Shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as follows:
|
|
Votes Cast FOR |
% of Vote Cast |
Votes WITHHELD |
% of Votes |
|
|
18,209,962 |
88.85 |
2,284,420 |
11.15 |
|
|
19,959,739 |
97.39 |
534,643 |
2.61 |
|
|
19,135,935 |
93.37 |
1,358,447 |
6.63 |
|
|
19,959,554 |
97.39 |
534,828 |
2.61 |
|
|
19,118,129 |
93.28 |
1,376,253 |
6.72 |
|
|
16,442,226 |
80.23 |
4,052,156 |
19.77 |
|
|
19,032,703 |
92.87 |
1,461,679 |
7.13 |
|
|
19,135,933 |
93.37 |
1,358,449 |
6.63 |
HLS also confirms that shareholders approved the appointment of
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
SOURCE
